<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253353</url>
  </required_header>
  <id_info>
    <org_study_id>B3461075</org_study_id>
    <nct_id>NCT04253353</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics</brief_title>
  <official_title>A PHASE 1, OPEN LABEL, TWO-PERIOD, TWO-TREATMENT, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF A MULTIPLE ORAL DOSE OF TAFAMIDIS ON ROSUVASTATIN PHARMACOKINETICS IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each subject will be given a single oral dose of rosuvastatin on Day 1 in Period 1. In Period
      2, after a washout period of at least 5 days, each subject will receive oral doses of
      tafamidis twice daily (BID) on days 1 and 2, followed by tafamidis once daily (QD) on days 3
      to 9 with an oral dose of rosuvastatin on Day 7. Rosuvastatin exposures will be compared
      between Periods 1 and 2 to estimate the effect of tafamidis on rosuvastatin PK in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Anticipated">May 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time 0 extrapolated to infinity (AUCinf) for rosuvastatin</measure>
    <time_frame>Hours 0, at 30 minutes and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose in Periods 1 and 2.</time_frame>
    <description>AUClast + (Clast/kel)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent renal clearance (CLr) for rosuvastatin</measure>
    <time_frame>Hours 0, at 30 minutes and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, and 72 hours post-dose in Periods 1 and 2 for AUClast. For Ae, hours 0-24, 24-48, 48-72 hours post-dose in Periods 1 and 2.</time_frame>
    <description>Ae/AUClast for extravascular dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with a clinically significant change in vital sign measurements from baseline</measure>
    <time_frame>Baseline through Day 10 of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with a clinically significant change in laboratory tests from baseline</measure>
    <time_frame>Baseline through Day 10 of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment emergent adverse events</measure>
    <time_frame>Baseline through Day 28 follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>rosuvastatin and tafamidis fixed sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: rosuvastatin 10 mg (single oral administration)
Washout
Period 2: tafamidis 61 mg capsule(multiple doses, twice a day) + rosuvastatin 10 mg (single oral administration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tafamidis</intervention_name>
    <description>61 mg capsule</description>
    <arm_group_label>rosuvastatin and tafamidis fixed sequence</arm_group_label>
    <other_name>Vyndaqel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>10 mg tablet</description>
    <arm_group_label>rosuvastatin and tafamidis fixed sequence</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female participants must be 18 to 60 years of age, inclusive, at the time of
             signing the informed consent document (ICD)

          -  Male and female participants who are overtly healthy as determined by medical
             evaluation including medical history, physical examination, laboratory tests, and
             cardiovascular tests

          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb)

        Exclusion Criteria:

        Participants are excluded from the study if any of the following criteria apply:

          -  History of hypersensitivity to rosuvastatin., asymptomatic, seasonal allergies at the
             time of dosing).

          -  Use of CYP2C19 inhibitors (eg, fluconazole, fluoxetine, fluvoxamine, ticlopidine
             omeprazole, voriconazole, cimetidine, esomeprazole, and felbamate) or inducers (eg,
             rifampin, ritonavir, efavirenz, enzalutamide, phenytoin, and St. John's Wort) within
             28 days or 5 half-lives (whichever is longer) prior to dosing.

          -  Use of CYP3A4 inhibitors (eg, ketoconazole, ciprofloxacin, diltiazem) or other
             inducers (eg, phenytoin, carbamazepine) within 28 days or 5 half-lives (whichever is
             longer) prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brussels Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-capitale, RÃ©gion DE</state>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B3461075</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

